Bioavailability study of oral liquid and tablet forms of α-difluoromethylornithine

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 3850-3854

  Carbone, Paul P ^a,b   Douglas, Jeffrey A ^a,b   Thomas, James ^a,b   Tutsch, Kendra ^a   Pomplun, Marcia ^a   Hamielec, Mary ^a   Pauk, Diane ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG HALF LIFE; HEARTBURN; HUMAN; HUMAN EXPERIMENT; LIQUID; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TABLET;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EFLORNITHINE; FEMALE; HUMANS; MALE; MIDDLE AGED; TABLETS; TIME FACTORS;

EID: 0033754970     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Modulation of mouse skin tumor promotion by dietary 13-cis-retinoic acid and α-difluoromethylornithine
2. Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment
3. Randomized Phase I chemoprevention dose-seeking study of α-difluoromethylornithine
4. Inhibition of ornithine decarboxylase activity by small doses of α-difluoromethylornithine
5. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy
6. A precolumn derivatization high-performance liquid chromatographic (HPLC) procedure for the quantification of difluoromethylornithine in plasma
7. α-Difluoromethylornithine as treatment for metastatic breast cancer patients
8. Evaluation of continuous-infusion α-difluoromethylornithine therapy for colorectal carcinoma
9. Treatment of recurrent gliomas with eflornithine
10. Ornithine decarboxylase as a target for chemoprevention
11. Chemoprevention of experimental bladder cancer
12. Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice
13. Prostaglandins and skin tumor promotion: Inhibition of tumor promoter-induced ornithine decarboxylase activity by inhibitors of prostaglandin synthesis
14. Kinetics of α-difluoromethylornithine: An irreversible inhibitor of ornithine decarboxylase
15. Polyamines regulate expression of the neoplastic phenotype in mouse skin
16. Suicide enzyme inhibitors as potential drugs
17. Inhibition of deoxyribonucleic acid synthesis by difluoromethylornithine. Role of polyamine metobolism in monocrotaline-induced pulmonary hypertension
18. Time dependence of the potentiation of 1,3-bis(2-chlorethyl)-1-nitrosourea cytotoxicity caused by α-difluoromethylornithine-induced polyamine depletion in 9L rat brain tumor cells
19. Evaluation of α-difluoromethylornithine as a potential chemopreventive agent: Tolerance to daily oral administration in humans
20. Inhibition of tumor promoter 12-O-tetradecanoylphorbol-13-acetate-induced synthesis of epidermal ornithine decarboxylase messenger RNA and diacylglycerol-promoted mouse skin tumor formation by retinoic acid
21. 14C]ornithine